About ProQuant™
ProQuant™ is now offered by RxCelerate following the acquisition of the proteomics team from Methuselah Health in 2022. Methuselah Health was founded in 2015 to discover drugs for age-related diseases driven by proteomic instability, and has developed the world’s most powerful proteomics platform to power its discovery efforts. RxCelerate was founded in 2013 with a vision to provide a bespoke high-quality outsourced drug discovery and development platform. Originally focused on delivering preclinical and in vitro biology services, during the last nine years we have expanded our in-house capabilities to include chemistry, in silico design, systems biology and project and programme management.
World leading proteomics platform
ProQuant™ is a world-leading proprietary platform for performing LC-MS/MS bottom-up proteomics on a wide range of biological samples, delivering precision unachievable by other proteomics platforms.
ProQuant™
Learn more about our proprietary technology.
Our Leadership Team
David Mosedale
CTO at Methuselah Health UK and previously CEO at Total Scientific, a small CRO specialising in biomarker discovery and VP of R&D at Pronostics, which developed CE-marked multiplex autoantibody assays using barcoded microparticles. David has 30 years experience in developing assays for hard-to-measure proteins and eliminating bias wherever he finds it.
Tilly Sharp
With a wealth of experience gained from performing academic and commercial scientific research as well as managing customer-lead research, Tilly now manages programmes using the ProQuant™ platform within RxCelerate.
Home
Technology
Our Services
Case Studies
Contact Us
Get in touch
Call Us 01223 839557
Email Us [email protected]
Visit Us
RxCelerate Ltd
Dorothy Hodgkin Building,
Babraham Research Campus,
Babraham, Cambridge CB22 3FH
